The global Non-invasive Prenatal Testing market is expected to exceed more than US$ 8 Billion by 2028 at a CAGR of 17% in the given forecast period.
The bioscience industry is targeted on the event of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the health care infrastructure square measure promoting the adoption of the NIPT for higher identification and improved prenatal care.
Non-invasive prenatal testing (NIPT) could be a subtle technique used for the screening of chromosomal abnormalities developing within the fetus. Currently, NIPT is taken into account as a valuable check for the pregnant ladies to supply cost-efficient and extremely economical early identification of genetic disorders. Moreover, advancements in order sequencing technologies cut back turnaround and also the quality of identification with next generation sequencing (NGS). The NGS technology provides many opportunities to develop the non-invasive diagnostic procedures for an early and correct detection of varied genetic disorders.
The major factors driving the expansion of this market embrace the growing preference for non-invasive techniques over invasive ways, rising specialize in compensation for NIPT, launch of recent and advanced NIPT merchandise, and increasing maternal age (associated with growth within the risk of body abnormalities in babies). moreover, untapped rising markets area unit expected to supply potential growth opportunities to players in operation within the NIPT market throughout the forecast amount.
Market Insights
The global Non-invasive Prenatal Testing market is segregated on the basis of Test as Verifi, MaterniT21 PLUS and MaterniT GENOME, PrenaTest, GeneSafe, and PrenatalSAFE, Panorama, QNatal Advanced, Harmony, IONA, NIFTY, and Bambni. Based on Method the global Non-invasive Prenatal Testing market is segmented in cf-DNA and FCMB. Based on Application the global Non-invasive Prenatal Testing market is segmented in Trisomy Detection, Microdeletion Detection, and Others.
Based on Platform, the global Non-invasive Prenatal Testing market is segmented in NGS, MPSS, Others,
The global Non-invasive Prenatal Testing market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Non-invasive Prenatal Testing market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Agilent Technologies, Inc., Annoroad Gene Technology, Berry Genomics Co., Ltd., BGI Diagnosis, FIllumina, Inc., Hoffmann-La Roche AG, Natera, Inc., NIPD Genetics, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and others are among the major players in the global Non-invasive Prenatal Testing market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Non-invasive Prenatal Testing Market has been segmented as below:
Non-invasive Prenatal Testing Market, By Test
Non-invasive Prenatal Testing Market, By Method
Non-invasive Prenatal Testing Market, By Application
Non-invasive Prenatal Testing Market, By Platform
Non-invasive Prenatal Testing Market, By Region
Non-invasive Prenatal Testing Market, By Company
The report covers:
Report Scope:
The global Non-invasive Prenatal Testing market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Non-invasive Prenatal Testing market share. Major industry players with significant revenue share include Agilent Technologies, Inc., Annoroad Gene Technology, Berry Genomics Co., Ltd., BGI Diagnosis, FIllumina, Inc., Hoffmann-La Roche AG, Natera, Inc., NIPD Genetics, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
Prosthetic Heart Valve/ Artificial Heart Valve Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Non-invasive Prenatal Testing Market, By Test
5.1 Introduction
5.2 Verifi
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 MaterniT21 PLUS and MaterniT GENOME
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 PrenaTest, GeneSafe, and PrenatalSAFE
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Panorama
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 QNatal Advanced
5.6.1 Market Overview
5.6.2 Market Size and Forecast
5.7 Harmony
5.7.1 Market Overview
5.7.2 Market Size and Forecast
5.8 IONA
5.8.1 Market Overview
5.8.2 Market Size and Forecast
5.9 NIFTY
5.9.1 Market Overview
5.9.2 Market Size and Forecast
5.10 Bambni
5.10.1 Market Overview
5.10.2 Market Size and Forecast
6. Non-invasive Prenatal Testing Market, By Method
6.1 Introduction
6.2 cf-DNA
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 FCMB
6.3.1 Market Overview
6.3.2 Market Size and Forecast
7. Non-invasive Prenatal Testing Market, By Application
7.1 Introduction
7.2 Trisomy Detection
7.2.1 Market Overview
7.2.2 Market Size and Forecast
7.3 Microdeletion Detection
7.3.1 Market Overview
7.3.2 Market Size and Forecast
7.4 Others
7.4.1 Market Overview
7.4.2 Market Size and Forecast
8. Non-invasive Prenatal Testing Market, By Platform
8.1 Introduction
8.2 NGS
8.2.1 Market Overview
8.2.2 Market Size and Forecast
8.3 MPSS
8.3.1 Market Overview
8.3.2 Market Size and Forecast
8.4 Others
8.4.1 Market Overview
8.4.2 Market Size and Forecast
9. Non-invasive Prenatal Testing Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 North America Non-invasive Prenatal Testing, By Test
9.2.2 North America Non-invasive Prenatal Testing, By Method
9.2.3 North America Non-invasive Prenatal Testing, By Application
9.2.4 North America Non-invasive Prenatal Testing, By Platform
9.3 Europe
9.3.1 Europe Non-invasive Prenatal Testing, By Test
9.3.2 Europe Non-invasive Prenatal Testing, By Method
9.3.3 Europe Non-invasive Prenatal Testing, By Application
9.3.4 Europe Non-invasive Prenatal Testing, By Platform
9.4 Asia-Pacific
9.4.1 Asia-Pacific Non-invasive Prenatal Testing, By Test
9.4.2 Asia-Pacific Non-invasive Prenatal Testing, By Method
9.4.3 Asia-Pacific Non-invasive Prenatal Testing, By Application
9.4.4 Asia-Pacific Non-invasive Prenatal Testing, By Platform
9.5 Rest of the World
9.5.1 Rest of the World Non-invasive Prenatal Testing, By Test
9.5.2 Rest of the World Non-invasive Prenatal Testing, By Method
9.5.3 Rest of the World Non-invasive Prenatal Testing, By Application
9.5.4 Rest of the World Non-invasive Prenatal Testing, By Platform
10. Competitive Insights
10.1 Key Insights
10.2 Company Market Share Analysis
10.3 Strategic Outlook
10.3.1 Mergers & Acquisitions
10.3.2 New Product Development
10.3.3 Portfolio/Production Capacity Expansions
10.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
10.3.5 Others
11. Company Profiles
11.1 Agilent Technologies, Inc.
11.1.1 Company Overview
11.1.2 Product/Service Landscape
11.1.3 Financial Overview
11.1.4 Recent Developments
11.2 Annoroad Gene Technology
11.2.1 Company Overview
11.2.2 Product/Service Landscape
11.2.3 Financial Overview
11.2.4 Recent Developments
11.3 Berry Genomics Co., Ltd.
11.3.1 Company Overview
11.3.2 Product/Service Landscape
11.3.3 Financial Overview
11.3.4 Recent Developments
11.4 BGI Diagnosis
11.4.1 Company Overview
11.4.2 Product/Service Landscape
11.4.3 Financial Overview
11.4.4 Recent Developments
11.5 FIllumina, Inc.
11.5.1 Company Overview
11.5.2 Product/Service Landscape
11.5.3 Financial Overview
11.5.4 Recent Developments
11.6 Hoffmann-La Roche AG
11.6.1 Company Overview
11.6.2 Product/Service Landscape
11.6.3 Financial Overview
11.6.4 Recent Developments
11.7 Natera, Inc.
11.7.1 Company Overview
11.7.2 Product/Service Landscape
11.7.3 Financial Overview
11.7.4 Recent Developments
11.8 NIPD Genetics
11.8.1 Company Overview
11.8.2 Product/Service Landscape
11.8.3 Financial Overview
11.8.4 Recent Developments
11.9 Quest Diagnostics Incorporated
11.9.1 Company Overview
11.9.2 Product/Service Landscape
11.9.3 Financial Overview
11.9.4 Recent Developments
11.10 Laboratory Corporation of America Holdings
11.10.1 Company Overview
11.10.2 Product/Service Landscape
11.10.3 Financial Overview
11.10.4 Recent Developments
The Non-invasive Prenatal Testing Market has been segmented as below:
Non-invasive Prenatal Testing Market, By Test
Non-invasive Prenatal Testing Market, By Method
Non-invasive Prenatal Testing Market, By Application
Non-invasive Prenatal Testing Market, By Platform
Non-invasive Prenatal Testing Market, By Region
Non-invasive Prenatal Testing Market, By Company
SUBSCRIBE TO OUR NEWSLETTERS
